Sequential mutations causing resistance to both Imatinib Mesylate and Dasatinib in a chronic myeloid leukaemia patient progressing to lymphoid blast crisis.
Stagno
Fabio
F
Stella
Stefania
S
Berretta
Salvatore
S
Massimino
Michele
M
Antolino
Agostino
A
Giustolisi
Rosario
R
Messina
Angelo
A
Di Raimondo
Francesco
F
Vigneri
Paolo
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001549:Benzamides; D001752:Blast Crisis / Q000188:drug therapy / Q000235:genetics*; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D008214:Lymphocytes / Q000187:drug effects / Q000473:pathology; D008875:Middle Aged; D009154:Mutation / Q000235:genetics*; D010879:Piperazines / Q000008:administration & dosage; D016133:Polymerase Chain Reaction; D011743:Pyrimidines / Q000008:administration & dosage; D012074:Remission Induction; D013844:Thiazoles / Q000008:administration & dosage
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; D000069439:Dasatinib